Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide (Len) and pomalidomide trigger anti-tumor activities in multiple myeloma (MM) by targetting cereblon and thereby impacting IZF1/3, c-Myc and IRF4. Histone deacetylase inhibitors (HDACi) also downregulate c-Myc. We therefore determined whether...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Cancer J
Autori principali: Hideshima, T, Cottini, F, Ohguchi, H, Jakubikova, J, Gorgun, G, Mimura, N, Tai, Y-T, Munshi, N C, Richardson, P G, Anderson, K C
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2015
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4476017/
https://ncbi.nlm.nih.gov/pubmed/25978432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.38
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi